Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2023	$ 22	$ 110,017,751	$ (110,243,753)	$ (225,980)
Balance, shares at Sep. 30, 2023	218,786
Sale of common stock, net of issuance costs	$ 16	3,916,927		3,916,943
Sale of common stock, net of issuance costs, shares	163,281
Retirement of shares in connection with reverse stock split
Retirement of shares in connection with reverse stock split, shares	(190)
Net share settlement of warrants
Net share settlement of warrants, shares	1,795
Share-based compensation		50,005		50,005
Net income (loss)			(1,168,509)	(1,168,509)
Balance at Dec. 31, 2023	$ 38	113,984,683	(111,412,262)	2,572,459
Balance, shares at Dec. 31, 2023	383,672
Balance at Sep. 30, 2023	$ 22	110,017,751	(110,243,753)	(225,980)
Balance, shares at Sep. 30, 2023	218,786
Net income (loss)				(4,308,639)
Balance at Jun. 30, 2024	$ 67	117,170,431	(114,552,392)	2,618,106
Balance, shares at Jun. 30, 2024	650,284
Balance at Dec. 31, 2023	$ 38	113,984,683	(111,412,262)	2,572,459
Balance, shares at Dec. 31, 2023	383,672
Exercise of warrants	$ 4	55,996		56,000
Exercise of warrants, shares	4,375
Share-based compensation		60,395		60,395
Net income (loss)			365,425	365,425
Issuance of common stock on vesting of restricted stock units and awards
Issuance of common stock on vesting of restricted stock units and awards, shares	976
Balance at Mar. 31, 2024	$ 42	114,101,074	(111,046,837)	3,054,279
Balance, shares at Mar. 31, 2024	389,023
Net share settlement of warrants	$ 9	(9)
Net share settlement of warrants, shares	92,493
Share-based compensation		60,395		60,395
Net income (loss)			(3,505,555)	(3,505,555)
Sale of common stock		62,019		62,019
Sale of common stock, net of issuance costs, shares	4,706
Exercise and modification of warrants, net of issuance costs	$ 16	2,946,952		2,946,968
Exercise and modification of warrants, net of issuance costs, shares	164,062
Balance at Jun. 30, 2024	$ 67	117,170,431	(114,552,392)	2,618,106
Balance, shares at Jun. 30, 2024	650,284
Balance at Sep. 30, 2024	$ 65	117,195,181	(117,680,985)	(485,739)
Balance, shares at Sep. 30, 2024	650,284
Sale of common stock, net of issuance costs	$ 105	7,622,514		7,622,619
Sale of common stock, net of issuance costs, shares	1,050,500
Retirement of shares in connection with reverse stock split
Retirement of shares in connection with reverse stock split, shares	(373)
Shares released from abeyance	$ 3	(3)
Shares released from abeyance, shares	32,375
Net share settlement of warrants
Net share settlement of warrants, shares	1,209
Exercise of warrants	$ 127	(127)
Exercise of warrants, shares	1,273,436
Share-based compensation		60,395		60,395
Net income (loss)			(3,160,706)	(3,160,706)
Balance at Dec. 31, 2024	$ 300	124,877,960	(120,841,691)	4,036,569
Balance, shares at Dec. 31, 2024	3,007,431
Balance at Sep. 30, 2024	$ 65	117,195,181	(117,680,985)	(485,739)
Balance, shares at Sep. 30, 2024	650,284
Net income (loss)				(10,427,632)
Balance at Jun. 30, 2025	$ 333	125,061,805	(128,108,617)	(3,046,479)
Balance, shares at Jun. 30, 2025	3,332,728
Balance at Dec. 31, 2024	$ 300	124,877,960	(120,841,691)	4,036,569
Balance, shares at Dec. 31, 2024	3,007,431
Sale of common stock, net of issuance costs	$ 10	116,805		116,815
Sale of common stock, net of issuance costs, shares	98,846
Net income (loss)			(3,491,122)	(3,491,122)
Issuance of common stock on vesting of restricted stock units and awards	$ 2	(2)
Issuance of common stock on vesting of restricted stock units and awards, shares	17,152
Balance at Mar. 31, 2025	$ 312	124,994,763	(124,332,813)	662,262
Balance, shares at Mar. 31, 2025	3,123,429
Shares released from abeyance	$ 16	(16)
Shares released from abeyance, shares	155,125
Net income (loss)			(3,775,804)	(3,775,804)
Sale of common stock	$ 5	67,058		67,063
Sale of common stock, net of issuance costs, shares	54,174
Balance at Jun. 30, 2025	$ 333	$ 125,061,805	$ (128,108,617)	$ (3,046,479)
Balance, shares at Jun. 30, 2025	3,332,728

Sonnet BioTherapeutics Holdings, Inc. 10-Q